The Filing Desk

Gyre Therapeutics vs Zhengye Biotechnology

Gyre Therapeutics GYRE · Zhengye Biotechnology ZYBT · Pharmaceuticals

Gyre Therapeutics reported revenue of $117 million in fiscal 2025, and Zhengye Biotechnology CN¥116 million in fiscal 2025, in different currencies. Gyre Therapeutics' revenue grew 10.2% in its latest year, and Zhengye Biotechnology's fell 37.6%. Gyre Therapeutics had an operating margin of 9.8%, against -60.6% at Zhengye Biotechnology. Free cash flow was −$0 million at Gyre Therapeutics and CN¥12 million at Zhengye Biotechnology.

Side by side

Gyre TherapeuticsZhengye Biotechnology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$117MCN¥116M
Revenue growth10.2%−37.6%
Revenue growth a year, last 5 years41.0%—
Gross margin95.3%20.5%
Operating margin9.8%−60.6%
Net margin8.5%−60.0%
Free cash flow−$0MCN¥12M
Free cash flow margin−0.1%10.6%
Return on capital9.7%−14.9%
Net debt to EBITDA−3.8x—
Dividends and buybacks$0MCN¥0M
Change in diluted share count0.9%3.7%
Last close$4.52$1.52
P/E at the last close——
Insider trades, last 12 monthssold $952,874—
Piotroski F-score4 of 93 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
In each company's own currency, fiscal years
Gyre TherapeuticsZhengye Biotechnology
Operating margin
Percent of revenue
Gyre TherapeuticsZhengye Biotechnology
Free cash flow
In each company's own currency. Cash from operations minus capital expenditure.
Gyre TherapeuticsZhengye Biotechnology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Gyre Therapeutics and Zhengye Biotechnology pages.